Testosterone has a bigger reputation than its evidence supports. It is widely believed to be the hormone that governs orgasm — take more and orgasm becomes easier, stronger, more reliable. The trials say something more specific and less dramatic: testosterone reliably affects desire and arousal, particularly in people whose levels are genuinely low, and its effect on orgasm itself is much less well-established.

That distinction matters, because it decides who benefits. Someone whose orgasms have become difficult but whose desire is intact is asking testosterone to do something the evidence does not show it does. Someone whose desire has fallen away alongside low measured levels is in a different position entirely.

This article covers what the trials show in men and in women — which are separate bodies of evidence with separate conclusions — and where the research is weaker than the marketing. It is not medical advice.

Desire and arousal, not orgasm

Sexual response has separable phases, and hormones do not move them equally. In both sexes, testosterone's measured effects concentrate in the earlier ones:

  • Desire — wanting sex, and how often you think about it.
  • Arousal — physical response, including erectile function and lubrication.
  • Orgasm — the reflex itself, which is governed more by neural and psychological factors than by testosterone.

So when a trial reports that testosterone "improved sexual function", it is usually reporting an increase in desire, arousal or the frequency of satisfactory sexual events — not a direct measurement of orgasm. Reading those headlines as claims about orgasm is the most common misunderstanding in this area.

Men: strongest evidence, with an important caveat

In men with genuinely low testosterone, the evidence for benefit is real. The TTrials randomised 790 men aged 65 or over with serum testosterone below 275 ng/dL to testosterone gel or placebo for a year. Treatment raised levels into the mid-normal range for younger men and produced significant increases in sexual activity, sexual desire and erectile function (Snyder et al., 2016).

A meta-analysis of 41 randomised trials reached a similar conclusion — testosterone improves erectile function and other aspects of sexual response in hypogonadal men. But it also detected publication bias, and once that was corrected statistically, the benefits for erectile function and libido remained significant only in trials that had pharmaceutical company support (Corona et al., 2014).

That finding does not make the effect unreal. It does mean the size of the effect in the published literature is probably flattering, and that "testosterone improves sexual function" is most defensible when it is attached to a specific group: men with measured low levels plus symptoms. Clinical guidelines reflect this, recommending treatment for confirmed hypogonadism rather than for sexual complaints in general (Bhasin et al., 2018).

Women: a different drug at a different dose

Testosterone in women is not a smaller version of the male treatment. It is used at doses in the normal female physiological range — far below those used in men — and it is prescribed for low sexual desire rather than for orgasm.

The largest synthesis pooled 36 randomised trials covering 8,480 women and found testosterone significantly increased satisfactory sexual event frequency, sexual desire and sexual pleasure (Islam et al., 2019). Note what those outcomes are: desire and pleasure. Orgasm was not the primary measure, and the evidence for a specific effect on orgasm is thin.

The Global Consensus Position Statement, endorsed by ten international societies, recommends testosterone only for postmenopausal women with hypoactive sexual desire disorder, at doses within the normal female range, and notes that it is not approved for this use in most countries (Davis et al., 2019). An international guideline for clinicians makes the same recommendation with more detail on monitoring (Parish et al., 2021).

Two practical consequences follow. First, "my testosterone is low" means something different in women, where the normal range is much lower and measurement is less reliable. Second, because female testosterone is generally off-label, it is often prescribed outside specialist care in a way that the guidelines do not support — particularly compounded preparations and doses well above the physiological range, for which there is little safety data.

Oestrogen, HRT, and why it is a separate question

Around menopause, the hormone most likely to be relevant to sexual function is oestrogen rather than testosterone — mainly because it affects comfort and lubrication, which in turn affect whether sex is pleasurable at all. A meta-analysis of 47 randomised trials examined hormone therapy for sexual function in perimenopausal and postmenopausal women and is the current synthesis of that evidence (Meziou et al., 2023).

That is a large enough subject to be worth its own treatment; the companion article on menopause and orgasm covers it in detail.

What to record if you are on it

Because the expected benefit is in desire and arousal rather than orgasm, tracking has to measure the right things — and measure them before you start, not after:

  • Desire and orgasm separately. If desire improves and orgasm does not, that is a real and expected result rather than a treatment failure, and it is a much more useful thing to report than "it's not working".
  • A baseline before the first dose. Testosterone's placebo response is substantial, and without a starting point you cannot tell an effect from expectation.
  • Dates of dose changes, since labs are usually taken at a specific point in the dosing cycle.
  • Enough sessions to see past noise. Weeks, not days.

The wider picture across other drug classes is in medication and orgasm.

The short version

Testosterone acts on desire and arousal far more reliably than on orgasm, and that holds in both men and women. In men the benefit is best established for confirmed low testosterone with symptoms, and the published effect sizes are probably inflated by publication bias. In women the evidence supports a role in low sexual desire after menopause at physiological doses, not as a general libido or orgasm treatment, and it remains off-label in most countries. If you are considering it, the question worth asking is not "will this make orgasm easier" but "is my desire or arousal the thing that actually changed" — because those are the outcomes the trials measured.

Sources

  1. Corona, G., Isidori, A. M., Buvat, J., et al. (2014). Testosterone Supplementation and Sexual Function: A Meta-Analysis Study. The Journal of Sexual Medicine, 11(6), 1577–1592. (41 randomised controlled trials. Detected publication bias: after correction, benefits for erectile function and libido held only in trials with pharmaceutical support.) https://doi.org/10.1111/jsm.12536
  2. Snyder, P. J., Bhasin, S., Cunningham, G. R., et al. (2016). Effects of Testosterone Treatment in Older Men. The New England Journal of Medicine, 374(7), 611–624. (The TTrials: 790 men aged 65 or over with serum testosterone below 275 ng/dL, treated for one year.) https://doi.org/10.1056/NEJMoa1506119
  3. Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://doi.org/10.1210/jc.2018-00229
  4. Islam, R. M., Bell, R. J., Green, S., et al. (2019). Safety and Efficacy of Testosterone for Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trial Data. The Lancet Diabetes & Endocrinology, 7(10), 754–766. (36 trials, 8,480 participants. Effects were on desire, pleasure and satisfactory sexual events rather than orgasm measured on its own.) https://doi.org/10.1016/S2213-8587(19)30189-5
  5. Davis, S. R., Baber, R., Panay, N., et al. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666. (Endorsed by ten international societies; recommends testosterone only for postmenopausal women with low sexual desire, at doses within the normal female range.) https://doi.org/10.1210/jc.2019-01603
  6. Parish, S. J., Simon, J. A., Davis, S. R., et al. (2021). International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. The Journal of Sexual Medicine, 18(5), 849–867. https://doi.org/10.1016/j.jsxm.2020.10.009
  7. Meziou, N., Scholfield, C., Taylor, C. A., et al. (2023). Hormone Therapy for Sexual Function in Perimenopausal and Postmenopausal Women: A Systematic Review and Meta-Analysis Update. Menopause, 30(6), 659–671. (47 randomised controlled trials; an update of the 2013 Cochrane review.) https://doi.org/10.1097/GME.0000000000002185